NeoGenomics Prices $275 Million Convertible Senior Notes Offering, Announces Strategic Capital Structure Moves
NeoGenomics, a leading oncology diagnostics company focused on enabling precision medicine through advanced testing solutions, has announced the pricing of its previously disclosed private offering of $275 million aggregate principal amount of 0.75% convertible senior notes due 2032. The offering is being conducted through a private placement to investors that are reasonably believed to be qualified institutional buyers under Rule 144A of the U.S. Securities Act of 1933, as amended.
Alongside the base offering, NeoGenomics has also granted initial purchasers an option to acquire up to an additional $41.25 million in aggregate principal amount of notes. This option may be exercised within a 13-day period starting from the initial issuance date of the notes. The transaction is expected to close on June 22, 2026, subject to customary closing conditions.
Overview of the Convertible Notes Structure
The newly issued securities will take the form of senior unsecured convertible notes, carrying an annual interest rate of 0.75%, payable semiannually in arrears on January 1 and July 1 each year. The first interest payment is scheduled for January 1, 2027.
The notes will mature on July 1, 2032, unless they are converted into equity, redeemed by the company, or repurchased prior to maturity under specified conditions.
As senior unsecured obligations, the notes will rank equally in right of payment with NeoGenomics’ other existing and future unsecured senior debt, but will not be backed by collateral.
Conversion Rights and Terms
Holders of the convertible notes will have the ability to convert their notes into cash, shares of NeoGenomics common stock, or a combination of both, at the company’s discretion, depending on the circumstances at the time of conversion.
Prior to April 1, 2032, noteholders may convert their notes only under certain conditions and during specified periods. After this date, holders may convert their notes at any time at their discretion up until the second scheduled trading day immediately preceding the maturity date.
The initial conversion rate has been set at 70.6140 shares of common stock per $1,000 principal amount of notes, which corresponds to an initial conversion price of approximately $14.16 per share of NeoGenomics common stock.
This conversion price reflects a premium of approximately 35% above the company’s last reported share price of $10.49 on the Nasdaq Capital Market as of June 16, 2026. This premium is typically structured to provide equity upside to investors while limiting near-term dilution risk to existing shareholders.
The conversion rate and conversion price are subject to customary anti-dilution adjustments in the event of corporate actions such as stock splits, dividends, or similar events.
Redemption Provisions
NeoGenomics retains the option to redeem the notes, in whole or in part, under specific conditions beginning July 6, 2029, and ending on the 51st scheduled trading day prior to maturity.
Redemption may occur only if the company’s common stock trades at or above 130% of the conversion price for a defined period. In such cases, NeoGenomics may choose to redeem the notes for cash at par value, plus accrued and unpaid interest up to the redemption date.
Additionally, the company may redeem the notes earlier if less than 15% of the originally issued aggregate principal amount remains outstanding, subject to other contractual conditions.
These provisions provide the company with flexibility to manage its capital structure if equity performance and market conditions are favorable in the future.
Capped Call Transactions to Mitigate Dilution
In connection with the pricing of the notes, NeoGenomics entered into privately negotiated capped call transactions with several financial institutions acting as option counterparties.
These capped call arrangements are designed to reduce potential dilution to existing shareholders upon conversion of the notes. They may also help offset cash payments that NeoGenomics would otherwise be required to make if the conversion value exceeds the principal amount of the notes.
However, these protections are subject to a cap price, initially set at $20.98 per share, which represents a 100% premium over the company’s last closing price of $10.49 on June 16, 2026.
While capped call transactions are commonly used in convertible debt offerings, they introduce structured hedge positions that may influence market trading dynamics, particularly around the company’s stock.
Market Activity and Hedging Implications
NeoGenomics noted that the option counterparties and their affiliates may engage in hedging activity related to the capped call transactions. This may include purchasing shares of NeoGenomics common stock or entering into derivative transactions tied to the company’s equity.
Such activity could occur concurrently with the pricing of the notes or shortly thereafter. The company cautioned that these hedging actions could affect the trading price of both the common stock and the convertible notes.
Additionally, the counterparties may adjust their hedge positions over time, including through buying or selling shares or derivatives in the secondary market. These actions could take place prior to maturity or during conversion-related observation periods.
Depending on market conditions, such activity may either increase or reduce volatility in NeoGenomics’ share price and may influence the economics of conversion for noteholders.
Expected Use of Proceeds
NeoGenomics expects to generate approximately $266.15 million in net proceeds from the offering after deducting underwriting discounts, commissions, and estimated offering expenses.
If the initial purchasers fully exercise their option to purchase additional notes, total net proceeds could increase to approximately $306.16 million.
The company has outlined a detailed capital allocation plan for the proceeds:
- Approximately $25 million will be used to fund the capped call transactions intended to reduce dilution risk.
- A portion of the proceeds, together with cash on hand, will be used to repurchase approximately $276 million of its 0.25% convertible senior notes due 2028 through privately negotiated transactions.
- Any remaining proceeds may be used for general corporate purposes, which could include working capital, strategic investments, or other corporate initiatives.
If the additional notes option is exercised, NeoGenomics expects to enter into additional capped call transactions using a portion of the incremental proceeds.
Strategic Debt Refinancing and Share Repurchases
As part of the broader transaction structure, NeoGenomics is also conducting simultaneous debt repurchases and equity-related transactions designed to optimize its capital structure.
The company has agreed to repurchase $276 million in outstanding convertible notes due 2028 at a total cost of approximately $263.19 million, including accrued interest. These transactions were executed through privately negotiated agreements with selected noteholders.
In addition, NeoGenomics may repurchase up to $25 million of its common stock through coordinated transactions involving the initial purchasers or their affiliates.
These concurrent activities reflect a coordinated effort to manage dilution, refinance existing obligations, and potentially improve the company’s long-term financial flexibility.
Management noted that these repurchases may also influence trading conditions for the company’s stock, potentially impacting pricing dynamics and investor behavior around the new convertible notes.
Market and Trading Considerations
The company highlighted that hedged investors in the existing 2028 notes may unwind or adjust their hedges as part of the repurchase process. This could involve purchasing shares of NeoGenomics common stock or engaging in derivative transactions.
Given the size of the transactions relative to average daily trading volume, such activity could have a meaningful impact on market liquidity and volatility in the short term.
NeoGenomics emphasized that while it cannot predict the magnitude or direction of these effects, such trading activity could influence both the price of its common stock and the valuation of the newly issued convertible notes.
Regulatory Framework and Offering Restrictions
The notes are being offered exclusively to institutional investors under Rule 144A of the Securities Act and have not been registered with the U.S. Securities and Exchange Commission or any other regulatory body.
As a result, neither the notes nor any shares of common stock issuable upon conversion may be publicly offered or sold in the United States unless they are registered or qualify for an exemption from registration requirements.
The offering does not constitute an offer to sell or a solicitation to purchase securities in any jurisdiction where such an offer would be unlawful.
NeoGenomics’ $275 million convertible senior notes offering represents a significant capital markets transaction aimed at strengthening the company’s financial position while maintaining flexibility for future growth.
Through a combination of low-coupon convertible debt, capped call hedging strategies, and simultaneous debt repurchases, the company is actively managing both dilution risk and balance sheet structure.
The transaction also reflects broader trends in the biotechnology and diagnostics sector, where companies increasingly use convertible instruments to access capital efficiently while balancing shareholder dilution concerns and long-term strategic investment needs.
As the offering closes and related hedging and repurchase activities unfold, market participants will closely monitor the impact on NeoGenomics’ share price, trading liquidity, and capital structure positioning in the months ahead.
Source link: https://www.businesswire.com/
